Skip to main content
PMC home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1992 Jun 1;175(6):1643–1651. doi: 10.1084/jem.175.6.1643

A role for complement receptor-like molecules in iron acquisition by Candida albicans

PMCID: PMC2119266  PMID: 1588285

Abstract

Candida albicans, an opportunistic fungal pathogen of humans, is dependent upon iron for growth. Consequently, human serum inhibits C. albicans growth due to the presence of high affinity iron-binding proteins that sequester serum iron, making it unavailable for use by the organism. We report that in the inhibitory environment of human serum, the growth of C. albicans can be restored by the addition of exogenous hemoglobin or heme, but not by protoporphyrin IX, the heme precursor that does not contain iron. We further report that C. albicans can utilize cell surface proteins that are homologues of the mammalian complement receptors (CR) to rosette complement-coated red blood cells (RBC) and obtain RBC-derived iron for growth. The ability of Candida to acquire RBC-derived iron under these conditions is dependent upon Candida-RBC rosetting mediated by CR-like molecules. Unopsonized RBC do not support Candida growth in serum, and restoration of Candida growth in serum by complement-opsonized RBC is inhibited by monoclonal antibodies to the human CR type 3 (CR3). In addition, activation of the human alternative pathway of complement by Candida leads to "bystander" deposition of C3 fragments on the surface of autologous, unopsonized RBC, generating the ligands necessary for Candida-RBC rosetting. These results suggest that C. albicans has evolved a unique strategy for acquiring iron from the host, which exploits the host complement system, and which may contribute to the pathogenic potential of the organism.

Full Text

The Full Text of this article is available as a PDF (1.6 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Armstrong D. Opportunistic infections in the acquired immune deficiency syndrome. Semin Oncol. 1987 Jun;14(2 Suppl 3):40–47. [PubMed] [Google Scholar]
  2. Bodey G. P. Candidiasis in cancer patients. Am J Med. 1984 Oct 30;77(4D):13–19. [PubMed] [Google Scholar]
  3. Bornside G. H., Bouis P. J., Jr, Cohn I., Jr Hemoglobin and Escherichia coli, a lethal intraperitoneal combination. J Bacteriol. 1968 May;95(5):1567–1571. doi: 10.1128/jb.95.5.1567-1571.1968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bullen J. J. The significance of iron in infection. Rev Infect Dis. 1981 Nov-Dec;3(6):1127–1138. doi: 10.1093/clinids/3.6.1127. [DOI] [PubMed] [Google Scholar]
  5. CAROLINE L., TASCHDJIAN C. L., KOZINN P. J., SCHADE A. L. REVERSAL OF SERUM FUNGISTASIS BY ADDITION OF IRON. J Invest Dermatol. 1964 Jun;42:415–419. doi: 10.1038/jid.1964.90. [DOI] [PubMed] [Google Scholar]
  6. Calderone R. A., Cihlar R. L., Lee D. D., Hoberg K., Scheld W. M. Yeast adhesion in the pathogenesis of endocarditis due to Candida albicans: studies with adherence-negative mutants. J Infect Dis. 1985 Oct;152(4):710–715. doi: 10.1093/infdis/152.4.710. [DOI] [PubMed] [Google Scholar]
  7. Calderone R. A., Linehan L., Wadsworth E., Sandberg A. L. Identification of C3d receptors on Candida albicans. Infect Immun. 1988 Jan;56(1):252–258. doi: 10.1128/iai.56.1.252-258.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Chattaway F. W., Odds F. C., Barlow A. J. An examination of the production of hydrolytic enzymes and toxins by pathogenic strains of Candida albicans. J Gen Microbiol. 1971 Aug;67(3):255–263. doi: 10.1099/00221287-67-3-255. [DOI] [PubMed] [Google Scholar]
  9. Corbi A. L., Kishimoto T. K., Miller L. J., Springer T. A. The human leukocyte adhesion glycoprotein Mac-1 (complement receptor type 3, CD11b) alpha subunit. Cloning, primary structure, and relation to the integrins, von Willebrand factor and factor B. J Biol Chem. 1988 Sep 5;263(25):12403–12411. [PubMed] [Google Scholar]
  10. Cutler J. E., Friedman L., Milner K. C. Biological and chemical characterization of toxic substances from Candida albicans. Infect Immun. 1972 Oct;6(4):616–627. doi: 10.1128/iai.6.4.616-627.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Cutler J. E. Putative virulence factors of Candida albicans. Annu Rev Microbiol. 1991;45:187–218. doi: 10.1146/annurev.mi.45.100191.001155. [DOI] [PubMed] [Google Scholar]
  12. Dabrowa N., Landau J. W., Newcomer V. D. The antifungal activity of physiologic saline in serum. J Invest Dermatol. 1965 Nov;45(5):368–377. doi: 10.1038/jid.1965.145. [DOI] [PubMed] [Google Scholar]
  13. Edwards J. E., Jr, Gaither T. A., O'Shea J. J., Rotrosen D., Lawley T. J., Wright S. A., Frank M. M., Green I. Expression of specific binding sites on Candida with functional and antigenic characteristics of human complement receptors. J Immunol. 1986 Dec 1;137(11):3577–3583. [PubMed] [Google Scholar]
  14. Eigentler A., Schulz T. F., Larcher C., Breitwieser E. M., Myones B. L., Petzer A. L., Dierich M. P. C3bi-binding protein on Candida albicans: temperature-dependent expression and relationship to human complement receptor type 3. Infect Immun. 1989 Feb;57(2):616–622. doi: 10.1128/iai.57.2.616-622.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Elin R. J., Wolff S. M. Effect of pH and iron concentration on growth of Candida albicans in human serum. J Infect Dis. 1973 Jun;127(6):705–708. doi: 10.1093/infdis/127.6.705. [DOI] [PubMed] [Google Scholar]
  16. Esterly N. B., Brammer S. R., Crounse R. G. The relationship of transferrin and iron to serum inhibition of Candida albicans. J Invest Dermatol. 1967 Nov;49(5):437–442. [PubMed] [Google Scholar]
  17. Friedman H. M., Cohen G. H., Eisenberg R. J., Seidel C. A., Cines D. B. Glycoprotein C of herpes simplex virus 1 acts as a receptor for the C3b complement component on infected cells. Nature. 1984 Jun 14;309(5969):633–635. doi: 10.1038/309633a0. [DOI] [PubMed] [Google Scholar]
  18. Fries L. F., Friedman H. M., Cohen G. H., Eisenberg R. J., Hammer C. H., Frank M. M. Glycoprotein C of herpes simplex virus 1 is an inhibitor of the complement cascade. J Immunol. 1986 Sep 1;137(5):1636–1641. [PubMed] [Google Scholar]
  19. Gilmore B. J., Retsinas E. M., Lorenz J. S., Hostetter M. K. An iC3b receptor on Candida albicans: structure, function, and correlates for pathogenicity. J Infect Dis. 1988 Jan;157(1):38–46. doi: 10.1093/infdis/157.1.38. [DOI] [PubMed] [Google Scholar]
  20. Gustafson K. S., Vercellotti G. M., Bendel C. M., Hostetter M. K. Molecular mimicry in Candida albicans. Role of an integrin analogue in adhesion of the yeast to human endothelium. J Clin Invest. 1991 Jun;87(6):1896–1902. doi: 10.1172/JCI115214. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Heidenreich F., Dierich M. P. Candida albicans and Candida stellatoidea, in contrast to other Candida species, bind iC3b and C3d but not C3b. Infect Immun. 1985 Nov;50(2):598–600. doi: 10.1128/iai.50.2.598-600.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Hendry A. T. Inhibition of catalase activity of Candida albicans by serum. Sabouraudia. 1972 Jul;10(2):193–204. [PubMed] [Google Scholar]
  23. Holzberg M., Artis W. M. Hydroxamate siderophore production by opportunistic and systemic fungal pathogens. Infect Immun. 1983 Jun;40(3):1134–1139. doi: 10.1128/iai.40.3.1134-1139.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Ismail A., Bedell G. W., Lupan D. M. Siderophore production by the pathogenic yeast, Candida albicans. Biochem Biophys Res Commun. 1985 Jul 31;130(2):885–891. doi: 10.1016/0006-291x(85)90499-1. [DOI] [PubMed] [Google Scholar]
  25. Lachmann P. J., Halbwachs L. The influence of C3b inactivator (KAF) concentration on the ability of serum to support complement activation. Clin Exp Immunol. 1975 Jul;21(1):109–114. [PMC free article] [PubMed] [Google Scholar]
  26. Levitz S. M., Diamond R. D. A rapid colorimetric assay of fungal viability with the tetrazolium salt MTT. J Infect Dis. 1985 Nov;152(5):938–945. doi: 10.1093/infdis/152.5.938. [DOI] [PubMed] [Google Scholar]
  27. Louria D. B., Smith J. K., Brayton R. G., Buse M. Anti-Candida factors in serum and their inhibitors. I. Clinical and laboratory observations. J Infect Dis. 1972 Feb;125(2):102–114. doi: 10.1093/infdis/125.2.102. [DOI] [PubMed] [Google Scholar]
  28. McNearney T. A., Odell C., Holers V. M., Spear P. G., Atkinson J. P. Herpes simplex virus glycoproteins gC-1 and gC-2 bind to the third component of complement and provide protection against complement-mediated neutralization of viral infectivity. J Exp Med. 1987 Nov 1;166(5):1525–1535. doi: 10.1084/jem.166.5.1525. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Mold C., Bradt B. M., Nemerow G. R., Cooper N. R. Epstein-Barr virus regulates activation and processing of the third component of complement. J Exp Med. 1988 Sep 1;168(3):949–969. doi: 10.1084/jem.168.3.949. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Moors M. A., Jones S. M., Klyczek K. K., Rogers T. J., Buckley H. R., Blank K. J. Effect of Friend leukemia virus infection on susceptibility to Candida albicans. Infect Immun. 1990 Jun;58(6):1796–1801. doi: 10.1128/iai.58.6.1796-1801.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Mosser D. M., Edelson P. J. The third component of complement (C3) is responsible for the intracellular survival of Leishmania major. 1987 May 28-Jun 3Nature. 327(6120):329–331. doi: 10.1038/327329b0. [DOI] [PubMed] [Google Scholar]
  32. Norris K. A., Bradt B., Cooper N. R., So M. Characterization of a Trypanosoma cruzi C3 binding protein with functional and genetic similarities to the human complement regulatory protein, decay-accelerating factor. J Immunol. 1991 Oct 1;147(7):2240–2247. [PubMed] [Google Scholar]
  33. Ollert M. W., Wadsworth E., Calderone R. A. Reduced expression of the functionally active complement receptor for iC3b but not for C3d on an avirulent mutant of Candida albicans. Infect Immun. 1990 Apr;58(4):909–913. doi: 10.1128/iai.58.4.909-913.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Pangburn M. K., Müller-Eberhard H. J. Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement. J Exp Med. 1980 Oct 1;152(4):1102–1114. doi: 10.1084/jem.152.4.1102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Perry R. D., Brubaker R. R. Accumulation of iron by yersiniae. J Bacteriol. 1979 Mar;137(3):1290–1298. doi: 10.1128/jb.137.3.1290-1298.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Pippard M. J., Johnson D. K., Finch C. A. Hepatocyte iron kinetics in the rat explored with an iron chelator. Br J Haematol. 1982 Oct;52(2):211–224. doi: 10.1111/j.1365-2141.1982.tb03883.x. [DOI] [PubMed] [Google Scholar]
  37. ROTH F. J., Jr, GOLDSTEIN M. I. Inhibition of growth of pathogenic yeasts by human serum. J Invest Dermatol. 1961 May;36:383–387. doi: 10.1038/jid.1961.59. [DOI] [PubMed] [Google Scholar]
  38. Ray T. L., Digre K. B., Payne C. D. Adherence of Candida species to human epidermal corneocytes and buccal mucosal cells: correlation with cutaneous pathogenicity. J Invest Dermatol. 1984 Jul;83(1):37–41. doi: 10.1111/1523-1747.ep12261661. [DOI] [PubMed] [Google Scholar]
  39. Ray T. L., Wuepper K. D. Activation of the alternative (properdin) pathway of complement by Candida albicans and related species. J Invest Dermatol. 1976 Dec;67(6):700–703. doi: 10.1111/1523-1747.ep12598581. [DOI] [PubMed] [Google Scholar]
  40. Shepherd M. G. Pathogenicity of morphological and auxotrophic mutants of Candida albicans in experimental infections. Infect Immun. 1985 Nov;50(2):541–544. doi: 10.1128/iai.50.2.541-544.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Simonson C., Brener D., DeVoe I. W. Expression of a high-affinity mechanism for acquisition of transferrin iron by Neisseria meningitidis. Infect Immun. 1982 Apr;36(1):107–113. doi: 10.1128/iai.36.1.107-113.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Sobel J. D., Muller G., Buckley H. R. Critical role of germ tube formation in the pathogenesis of candidal vaginitis. Infect Immun. 1984 Jun;44(3):576–580. doi: 10.1128/iai.44.3.576-580.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Sohnle P. G., Frank M. M., Kirkpatrick C. H. Deposition of complement components in the cutaneous lesions of chronic mucocutaneous candidiasis. Clin Immunol Immunopathol. 1976 May;5(3):340–350. doi: 10.1016/0090-1229(76)90043-x. [DOI] [PubMed] [Google Scholar]
  44. Sohnle P. G., Kirkpatrick C. H. Deposition of complement in the lesions of experimental cutaneous candidiasis in guinea pigs. J Cutan Pathol. 1976;3(5):232–238. doi: 10.1111/j.1600-0560.1976.tb00868.x. [DOI] [PubMed] [Google Scholar]
  45. Stull T. L. Protein sources of heme for Haemophilus influenzae. Infect Immun. 1987 Jan;55(1):148–153. doi: 10.1128/iai.55.1.148-153.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Whimbey E., Kiehn T. E., Brannon P., Blevins A., Armstrong D. Bacteremia and fungemia in patients with neoplastic disease. Am J Med. 1987 Apr;82(4):723–730. doi: 10.1016/0002-9343(87)90007-6. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES